CN115989026A - 三硫化物化合物及其包合物 - Google Patents

三硫化物化合物及其包合物 Download PDF

Info

Publication number
CN115989026A
CN115989026A CN202180050746.1A CN202180050746A CN115989026A CN 115989026 A CN115989026 A CN 115989026A CN 202180050746 A CN202180050746 A CN 202180050746A CN 115989026 A CN115989026 A CN 115989026A
Authority
CN
China
Prior art keywords
group
carbon atoms
cyclodextrin
substituents
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180050746.1A
Other languages
English (en)
Chinese (zh)
Inventor
朝长昌一郎
矶部贵弘
大岛悦男
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xiehe Pharmaceutical Chemical Co ltd
Original Assignee
Xiehe Pharmaceutical Chemical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xiehe Pharmaceutical Chemical Co ltd filed Critical Xiehe Pharmaceutical Chemical Co ltd
Publication of CN115989026A publication Critical patent/CN115989026A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
    • C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D341/00—Heterocyclic compounds containing rings having three or more sulfur atoms as the only ring hetero atoms
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
    • C08L5/16—Cyclodextrin; Derivatives thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
CN202180050746.1A 2020-08-27 2021-08-25 三硫化物化合物及其包合物 Pending CN115989026A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020143645 2020-08-27
JP2020-143645 2020-08-27
PCT/JP2021/031222 WO2022045212A1 (ja) 2020-08-27 2021-08-25 トリスルフィド化合物及びその包接体

Publications (1)

Publication Number Publication Date
CN115989026A true CN115989026A (zh) 2023-04-18

Family

ID=80355339

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180050746.1A Pending CN115989026A (zh) 2020-08-27 2021-08-25 三硫化物化合物及其包合物

Country Status (5)

Country Link
US (1) US12552764B2 (https=)
EP (1) EP4194448A4 (https=)
JP (1) JP7684315B2 (https=)
CN (1) CN115989026A (https=)
WO (1) WO2022045212A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7842033B2 (ja) 2020-05-12 2026-04-07 ザ ジェネラル ホスピタル コーポレイション 神経保護におけるグルタチオントリスルフィド（ｇｓｓｓｇ）
EP4342464A4 (en) 2021-07-08 2025-06-04 Kyowa Pharma Chemical Co., Ltd. PROPHYLACTIC OR THERAPEUTIC MEDICINE FOR PARKINSON'S DISEASE
TW202321270A (zh) * 2021-09-09 2023-06-01 國立大學法人九州大學 使用三硫化合物之防止肝細胞增殖因子中之酪胺酸殘基之硝基化的方法
EP4603087A1 (en) 2022-11-21 2025-08-20 Kyowa Hakko Bio Co., Ltd. Prophylactic or therapeutic agent for acute kidney injury induced by anticancer agent
CN115716817B (zh) * 2022-11-22 2024-04-19 国药集团威奇达药业有限公司 6,8-环三硫辛酸的制备方法
CN120390743A (zh) 2022-12-27 2025-07-29 协和医药化工股份有限公司 三硫化物化合物及其包合物
EP4647072A1 (en) 2023-03-07 2025-11-12 Kyowa Hakko Bio Co., Ltd. Enhancer of physiological activity of hepatocyte growth factor
WO2025028521A1 (ja) 2023-08-01 2025-02-06 キリンホールディングス株式会社 肝機能障害の予防又は改善用組成物
WO2025070464A1 (ja) 2023-09-28 2025-04-03 協和ファーマケミカル株式会社 トリスルフィド化合物を含有する医薬組成物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107652264A (zh) * 2017-09-25 2018-02-02 苏州华诺医药有限公司 硫辛酸杂质a的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS377970B1 (https=) 1959-12-08 1962-07-11
DE4338508A1 (de) 1993-11-11 1995-05-18 Asta Medica Ag Arzneimittelzubereitungen enthaltend Thioctsäure oder Dihydroliponsäure in Form von Einschlußverbindungen mit Cyclodextrinen oder Cyclodextrinderivaten und in Form von Granulaten, Kau- oder Brausetabletten
CN1232539C (zh) 2002-05-10 2005-12-21 刘云清 有机药物与倍他环糊精衍生物的配合物及其制备方法
EP1707217A1 (en) * 2004-12-17 2006-10-04 Wacker Chemie AG Process for preparing an alpha lipoic acid/cyclodextrin complex and product prepared
CN101607955B (zh) * 2008-06-18 2012-11-28 上海津力化工有限公司 一种低残留硫辛酸的制备方法
JOP20190057A1 (ar) 2016-09-23 2019-03-24 Encore Vision Inc تركيبات استر كولين حمض الليبويك وطرق تثبيتها إلى منتجات عقار ذات صلة دوائية
CN111320603A (zh) 2018-12-13 2020-06-23 江苏同禾药业有限公司 一种硫辛酸工艺杂质的制备方法
EP4342464A4 (en) * 2021-07-08 2025-06-04 Kyowa Pharma Chemical Co., Ltd. PROPHYLACTIC OR THERAPEUTIC MEDICINE FOR PARKINSON'S DISEASE

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107652264A (zh) * 2017-09-25 2018-02-02 苏州华诺医药有限公司 硫辛酸杂质a的制备方法

Also Published As

Publication number Publication date
US20230331692A1 (en) 2023-10-19
EP4194448A1 (en) 2023-06-14
US12552764B2 (en) 2026-02-17
WO2022045212A1 (ja) 2022-03-03
JP7684315B2 (ja) 2025-05-27
JPWO2022045212A1 (https=) 2022-03-03
EP4194448A4 (en) 2025-05-07

Similar Documents

Publication Publication Date Title
CN115989026A (zh) 三硫化物化合物及其包合物
EP3566719A1 (en) Compositions and methods for treatment of autoimmune and other diseases
WO2008047057A1 (fr) Procede de preparation d'oligomeres ou polymeres de cyclodextrines, produits obtenus et utilisations
CN115943140B (zh) 三硫化物化合物
US20240374561A1 (en) Method for preventing nitration of tyrosine residues in hepatocyte growth factor using trisulfide compound
CN117320709A (zh) 帕金森病的预防或治疗药
FR2714067A1 (fr) Nouveaux dérivés de cyclodextrines, utilisables en particulier pour solubiliser des composés chimiques hydrophobes tels que des médicaments, et leur procédé de préparation.
KR101128450B1 (ko) 안정화제로서 β-싸이클로덱스트린 유도체를 포함하는 조성물
EP4613743A1 (en) Trisulfide compound and clathrate thereof
HU214338B (hu) Eljárás taxoltartalmú ciklodextrin zárványtermék előállítására
EP0886654B1 (fr) Thioureido-cyclodextrines, utilisables en particulier pour solubiliser des agents antitumoraux et antiparasitaires et leurs procedes de preparation
AU2013229355A1 (en) Sulforaphane-derived compounds, production method thereof and the medical, food and cosmetic use of same
EP0735879B1 (fr) Utilisation de cyclodextrines aminees pour la solubilisation aqueuse des dibenzazepines utilisables comme agent anti-epileptique
JPS6036490A (ja) 水溶性リフアンピシン誘導体
WO1995019994A1 (fr) Procede de solubilisation dans un milieu aqueux d'agents antitumoraux de la famille du taxol, et cyclodextrines ramifiees utilisables pour cette solubilisation
KR20070088802A (ko) 에포틸론을 포함하는 조성물 및 제조 방법
CN116178700B (zh) Peg化吲哚菁染料偶联紫杉醇前药型化合物及其制备和应用
CN120344503A (zh) 三硫化物化合物
EP4714441A1 (en) Composition for preventing or alleviating hepatic dysfunction
CN101010104A (zh) 包含苯并咪唑衍生物的稳定药物组合物及其制备方法
EP4647072A1 (en) Enhancer of physiological activity of hepatocyte growth factor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination